0       0

AST 2013 - Cutting Edge of Transplantation


SA05 - IVIG with and without Anti-B Cell Targeting (Desensitization and Therapy)


Feb 16, 2013 10:30am ‐ Feb 16, 2013 11:00am

Description

I will be discussing current methods for desensitization as well as ongoing clinical trials we are conducting. Currently, there are several unresolved controversies and questions regarding the efficacy and economics of desensitization. I will address these and hopefully help clarify some of the outstanding controversies. I would hope that the audience would come away with a better understanding of the options and opportunities for transplantation that are created by desensitization. Also, what the future holds and how to refine desensitization protocols to insure the appropriate patients are treated and parameters for choosing an appropriate kidney for each patient are clearly defined.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content